Ardent Health, Inc.
Close on Oct 19, 2026
- Market cap
- $1.67B
- P/E (TTM)
- 21.3
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | $1.62B | $0.12 | $0.12 |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | During market hours | $1.60B | $0.28 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | During market hours | $1.61B | $0.32 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | During market hours | $1.58B | $-0.17 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | During market hours | $1.65B | $0.52 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | $1.50B | $0.29 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | During market hours | $1.45B | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $1.45B | $0.19 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | Full Year 2026 | $225.00M to $265.00M | Maintained |
| Adjusted EBITDAnon-GAAP | Full Year 2026 | $485.00M to $535.00M | Maintained |
| Diluted earnings per shareGAAP | Full Year 2026 | $0.78 to $1.15 | Lowered |
| Adjusted admissions growth | Full Year 2026 | 1.5% to 2.5% growth | Maintained |
| Rent expense payable to REITs | Full Year 2026 | $168.00M | Maintained |
| Total revenue | Full Year 2026 | $6.40B to $6.70B | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Ardent Health filed with the SEC
The following sections of “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of
Other events · EX-99.1 to Form 8-K
Ardent Health Reports Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Ardent Health Appoints Dave Caspers as CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Ardent Health Reports First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Ardent Health Reports Fourth Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Ardent Health Announces $50 Million Share Repurchase
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Ardent Health Reports Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Ardent Health Reports Second Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Ardent Health Reports First Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99 to Form 8-K
Results of operations · Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
Ardent Health Reports Third Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Ardent Health Reports Second Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K